SG11201701377YA - Compositions and methods to treat vision disorders - Google Patents

Compositions and methods to treat vision disorders

Info

Publication number
SG11201701377YA
SG11201701377YA SG11201701377YA SG11201701377YA SG11201701377YA SG 11201701377Y A SG11201701377Y A SG 11201701377YA SG 11201701377Y A SG11201701377Y A SG 11201701377YA SG 11201701377Y A SG11201701377Y A SG 11201701377YA SG 11201701377Y A SG11201701377Y A SG 11201701377YA
Authority
SG
Singapore
Prior art keywords
compositions
methods
vision disorders
treat vision
treat
Prior art date
Application number
SG11201701377YA
Other languages
English (en)
Inventor
Kang Zhang
Rui Hou
Original Assignee
Kang Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kang Zhang filed Critical Kang Zhang
Publication of SG11201701377YA publication Critical patent/SG11201701377YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
SG11201701377YA 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders SG11201701377YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040721P 2014-08-22 2014-08-22
US201562194120P 2015-07-17 2015-07-17
PCT/US2015/046453 WO2016029199A1 (en) 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders

Publications (1)

Publication Number Publication Date
SG11201701377YA true SG11201701377YA (en) 2017-03-30

Family

ID=55351326

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701377YA SG11201701377YA (en) 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders

Country Status (13)

Country Link
US (1) US10471076B2 (ja)
EP (1) EP3182977B1 (ja)
JP (1) JP6706020B2 (ja)
KR (1) KR20170048426A (ja)
CN (2) CN107206009B (ja)
AU (1) AU2015305199A1 (ja)
BR (1) BR112017003529A2 (ja)
CA (1) CA2958868A1 (ja)
EA (1) EA035798B1 (ja)
HK (1) HK1243325A1 (ja)
MX (1) MX2017002374A (ja)
SG (1) SG11201701377YA (ja)
WO (1) WO2016029199A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206009B (zh) 2014-08-22 2020-03-27 广州康睿生物医药科技股份有限公司 用于治疗视觉障碍的组合物和方法
CA2993196A1 (en) * 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts
CN109364019B (zh) * 2015-09-02 2021-12-28 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
CN106344587A (zh) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
CN109415406B (zh) * 2017-01-25 2019-08-06 中山大学中山眼科中心 羊毛甾醇前药化合物及其制备方法和应用
US20200281944A1 (en) * 2017-11-17 2020-09-10 Mahmood Piraee Combinations Of Lanosterol Or 25-Hydroxycholesterol Including Derivatives Thereof Useful In The Treatment Of Lens Disorders
CN109985052A (zh) * 2017-12-29 2019-07-09 上海蓝木化工有限公司 三萜类化合物的新用途
WO2019195761A2 (en) * 2018-04-05 2019-10-10 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
JP7046266B2 (ja) * 2018-07-25 2022-04-01 グアンジョウ オクスン オフサルミク バイオテクノロジー カンパニーリミテッド ラノステロールプロドラッグ化合物の結晶形及びその使用
MX2021009520A (es) 2021-08-06 2023-02-07 Foodvica S A De C V Composicion oftalmica para el tratamiento de trastornos visuales.
CN115737654A (zh) 2021-09-03 2023-03-07 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN116570706A (zh) * 2022-02-09 2023-08-11 上海瑞吉康生物医药有限公司 使用多肽治疗白内障的方法
WO2023198192A1 (zh) * 2022-04-15 2023-10-19 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗老花眼的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2005084208A2 (en) * 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
CN101959503A (zh) * 2008-02-29 2011-01-26 财团法人名古屋产业科学研究所 眼后节到达用脂质体和眼后节疾病用医药组合物
MX2011001411A (es) * 2008-08-05 2011-03-15 Amazonia Fitomedicamentos Ltda Usos farmaceuticos de lanosta-8,24-dien-3-ols.
NZ704266A (en) 2012-07-17 2017-09-29 Univ Michigan Regents Inhibitors of alpha-crystallin aggregation for the treatment for cataract
CA2881745A1 (en) * 2012-08-31 2014-03-06 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
CN107206009B (zh) 2014-08-22 2020-03-27 广州康睿生物医药科技股份有限公司 用于治疗视觉障碍的组合物和方法

Also Published As

Publication number Publication date
AU2015305199A1 (en) 2017-04-13
EP3182977A4 (en) 2018-04-11
KR20170048426A (ko) 2017-05-08
HK1243325A1 (zh) 2018-07-13
JP2017525769A (ja) 2017-09-07
EP3182977A1 (en) 2017-06-28
CN111529481A (zh) 2020-08-14
CN107206009B (zh) 2020-03-27
EA201790397A1 (ru) 2017-08-31
CN111529481B (zh) 2023-09-15
MX2017002374A (es) 2017-09-15
BR112017003529A2 (pt) 2019-08-20
WO2016029199A1 (en) 2016-02-25
US20170065617A1 (en) 2017-03-09
EP3182977B1 (en) 2021-05-05
EA035798B1 (ru) 2020-08-12
US10471076B2 (en) 2019-11-12
JP6706020B2 (ja) 2020-06-03
CA2958868A1 (en) 2016-02-25
CN107206009A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
HK1243325A1 (zh) 用於治療視覺障礙的組合物和方法
IL251066A0 (en) Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
ZA201607540B (en) Compositions and methods to treating hemoglobinopathies
IL246791A0 (en) Compositions and methods for treating eye diseases
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
IL247699A0 (en) Preparations and methods for the treatment of kidney disorders
HUE049518T2 (hu) Készítmények és eljárások a szem megbetegedéseinek kezelésére és diagnosztizálására
HK1245127A1 (zh) 治療腦疾病的方法和組合物
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
IL250114B (en) Methods and compositions for the treatment of HIV-related diseases
HK1246206A1 (zh) 用於治療青光眼的組合物和方法
EP3262065C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
HK1225994A1 (zh) 用於治療過敏性病症的組合物
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
IL252600A0 (en) Preparations for the treatment of hyperproliferation
GB201419559D0 (en) Therapeutic compositions and methods